Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

被引:6
|
作者
Shibasaki, Yuta [1 ]
Yokobori, Takehiko [2 ]
Sohda, Makoto [1 ]
Shioi, Ikuma [1 ]
Ozawa, Naoya [1 ]
Komine, Chika [1 ]
Suga, Kunihiko [1 ]
Nakazawa, Nobuhiro [1 ]
Osone, Katsuya [1 ]
Shiraishi, Takuya [1 ]
Okada, Takuhisa [1 ]
Sano, Akihiko [1 ]
Sakai, Makoto [1 ]
Ogawa, Hiroomi [1 ]
Kaira, Kyoichi [3 ]
Shirabe, Ken [1 ]
Saeki, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi 3718510, Japan
[2] Gunma Univ Initiat Adv Res GIAR, Div Integrated Oncol Res, Maebashi 3718511, Japan
[3] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka 3501298, Japan
基金
日本学术振兴会;
关键词
L-type amino acid transporter-1; cancer aggressiveness; prognostic marker; chemosensitivity marker; TRANSPORTER; FLUOROURACIL; LEUCOVORIN; LEVAMISOLE; RESISTANCE; THERAPY; ASCT2;
D O I
10.3390/ijms24032604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.
引用
收藏
页数:13
相关论文
共 50 条
  • [2] Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
    Dae-Won Lee
    Sae-Won Han
    Yongjun Cha
    Jeong Mo Bae
    Hwang-Phill Kim
    Jaemyun Lyu
    Hyojun Han
    Hyoki Kim
    Hoon Jang
    Duhee Bang
    Jae-Kyung Won
    Seung-Yong Jeong
    Kyu Joo Park
    Gyeong Hoon Kang
    Tae-You Kim
    BMC Cancer, 19
  • [3] Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
    Lee, Dae-Won
    Han, Sae-Won
    Cha, Yongjun
    Bae, Jeong Mo
    Kim, Hwang-Phill
    Lyu, Jaemyun
    Han, Hyojun
    Kim, Hyoki
    Jang, Hoon
    Bang, Duhee
    Won, Jae-Kyung
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Kim, Tae-You
    BMC CANCER, 2019, 19 (1)
  • [4] Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy
    Kaneko, Manabu
    Nozawa, Hiroaki
    Sasaki, Kazuhito
    Hongo, Kumiko
    Hiyoshi, Masaya
    Tada, Noriko
    Murono, Koji
    Nirei, Takako
    Kawai, Kazushige
    Sunami, Eiji
    Tsuno, Nelson H.
    Kitayama, Joji
    ONCOLOGY, 2012, 82 (05) : 261 - 268
  • [5] Validation of genetic markers for prognosis in colon cancer patients treated with oxaliplatin-based chemotherapy
    Park, Hanla
    Seibold, Petra
    Edelmann, Dominic
    Benner, Axel
    Jansen, Lina
    Canzian, Federico
    Schneider, Martin
    Hoffmeister, Michael
    Brenner, Hermann
    Chang-Claude, Jenny
    GENETIC EPIDEMIOLOGY, 2020, 44 (05) : 509 - 509
  • [6] phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
    Kotaka, M.
    Ishibashi, K.
    Satake, H.
    Tsuji, Y.
    Kataoka, M.
    Nakamura, M.
    Nagata, N.
    Sakamoto, J.
    Oba, K.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S101
  • [7] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
    Keiichiro Ishibashi
    Toru Aoyama
    Masahito Kotaka
    Hironaga Satake
    Yasushi Tsuji
    Masato Kataoka
    Masato Nakamura
    Naoki Nagata
    Junichi Sakamoto
    Koji Oba
    Hideyuki Mishima
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 665 - 672
  • [8] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
    Ishibashi, Keiichiro
    Aoyama, Toru
    Kotaka, Masahito
    Satake, Hironaga
    Tsuji, Yasushi
    Kataoka, Masato
    Nakamura, Masato
    Nagata, Naoki
    Sakamoto, Junichi
    Oba, Koji
    Mishima, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 665 - 672
  • [9] Reinduction of oxaliplatin-based chemotherapy after exposure to oxaliplatin in adjuvant setting for colorectal cancer.
    Beom, Seung-Hoon
    Ahn, Joong Bae
    Shin, Sang Joon
    Jung, Minkyu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [10] Association of MGMT-535G>T polymorphism with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Chae, Y.
    Kim, J.
    Sohn, S.
    Kang, B.
    Ryoo, H.
    Bae, S.
    Choi, G.
    Baek, J.
    Kim, Y.
    Cho, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)